Positive influence of 177Lu PSMA-617 therapy on bone marrow depression caused by metastatic prostate cancer

Clinical Nuclear Medicine

Volumn 41, Issue 6, 2016, Pages 478-480

  Schlenkhoff, Carl Diedrich ^a   Gaertner, Florian ^a   Essler, Markus ^a   Schmidt, Matthias ^b   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Medical Center Bonn   (Germany)

Author keywords

177Lu PSMA therapy; 68Ga PSMA PET CT; Anemia; Bone marrow depression; Castrate resistant; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; ENZALUTAMIDE; HEMOGLOBIN; MEDRONATE TECHNETIUM TC 99M; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; RA 223; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; EDETIC ACID; GALLIUM; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); OLIGOPEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM CHLORIDE RA 223; SINGLE HETEROCYCLIC RINGS;

AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BONE MARROW METASTASIS; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIOISOTOPE THERAPY; ANALOGS AND DERIVATIVES; BLOOD; BONE MARROW DISEASES; BONE NEOPLASMS; CHEMICALLY INDUCED; COMPASSIONATE USE; DIAGNOSTIC IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SCINTISCANNING; SECONDARY;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; BONE NEOPLASMS; COMPASSIONATE USE TRIALS; DIPEPTIDES; EDETIC ACID; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; OLIGOPEPTIDES; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RADIUM; TECHNETIUM TC 99M MEDRONATE;

EID: 84959115589     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001195     Document Type: Article

References (8)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467-479.
2. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987-988.
3. Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5:114.
4. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42: 197-209.
5. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
6. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-1705.
7. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48: 326-334.
8. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-992.